尿液中趋化因子免IP-10水平在兔抗人T淋巴细胞疫球蛋白临床应用中的指导

发布时间：2018-04-04 16:32

  本文选题：ATG　切入点：急性细胞性排斥反应　出处：《实用医学杂志》2017年07期

【摘要】：目的:探讨肾移植术后尿液中IP-10在ATG治疗急性细胞性排斥反应时剂量及疗程评估方面的应用价值。方法:收集肾移植术后病理确诊为急性细胞性排斥反应的患者40例,随机将其分为IP-10组(n=20)和Scr组(n=20),测定此时两组患者尿IP-10和Scr水平,之后给予ATG治疗,并分别将IP-10和Scr水平变化作为ATG剂量调整依据及停药标准,观察IP-10组和Scr组ATG疗程、人均日剂量、人均总剂量、严重血小板及中性粒细胞减少发生率、3月内急性排斥反应再发生率、1年内感染发生率。结果:平均用药时间IP-10组(5.35±1.93)d,Scr组(6.70±1.75)d;人均ATG日剂量IP-10组(2.50±0.57)mg(/kg·d),Scr组(2.77±0.74)mg(/kg·d);人均ATG总剂量IP-10组(13.40±6.59)mg/kg,Scr组(18.25±7.35)mg/kg。三项指标两组间均存在显著性差异(P0.05)。严重血小板及中性粒细胞减少发生率、3个月内急性排斥反应再发生率以及1年内感染发生率两组间无明显差异(P0.05)。结论:尿IP-10检测法能够有效、可靠指导肾移植术后急性细胞性排斥反应患者ATG使用,降低ATG治疗费用。
[Abstract]:Objective: to evaluate the value of IP-10 in urine after renal transplantation in the evaluation of dosage and course of treatment of acute cellular rejection with ATG.Methods: forty patients with acute cellular rejection after renal transplantation were randomly divided into IP-10 group (n = 20) and Scr group (n = 20). The levels of urinary IP-10 and Scr were measured, and then ATG was given.The changes of IP-10 and Scr levels were taken as the basis of ATG dose adjustment and withdrawal criteria, respectively. The course of ATG treatment, the daily dose per person and the total dose per capita in IP-10 group and Scr group were observed.The incidence of severe thrombocytopenia and neutropenia, acute rejection within 3 months and infection within 1 year.缁撴灉:骞冲潎鐢ㄨ嵂鏃堕棿IP-10缁，

本文编号：1710766